Thrombosis News and Research

Latest Thrombosis News and Research

Ariad Ends Phase III Leukemia Drug Trial

...

18 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Detecting dangerous blood clots in the form of simple urine test

Detecting dangerous blood clots, which can cause life-threatening conditions such as strokes and heart attacks, leading causes of death for men and women in the U.S., has been a coveted and elusive goal.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Simple urine test uses nanotechnology to detect dangerous blood clotting

Life-threatening blood clots can form in anyone who sits on a plane for a long time, is confined to bed while recovering from surgery, or takes certain medications.

17 Oct 2013

Sexual dysfunction ‘ignored in COPD’

Researchers say that physicians should address sexual issues in patients with chronic obstructive pulmonary disease as a matter of course, after finding that over three-quarters of men with the condition have some level of erectile dysfunction.

15 Oct 2013

Six-month surgery delay ‘acceptable’ after DES implantation

The recommendation to delay noncardiac surgery for a year after receipt of a drug-eluting stent, compared with just 6 weeks for a bare-metal stent, may be too conservative, suggests research indicating that stent type does not influence the longer term risk for major adverse cardiac events.

14 Oct 2013

Scientists introduce new approach to the production of synthetic heparin mimetics

One of the risks of any large operation is the occurrence of blood clots. To prevent this, patients are routinely given the anticoagulant heparin or related drugs. American scientists have now introduced a new approach to the production of synthetic heparin mimetics with better activity profiles.

11 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Understanding the biological players in clot formation could lead to new thrombotic therapies

Ulhas Naik, professor of biological sciences and director of the Delaware Cardiovascular Research Center, pores over laboratory data on his computer, even during breakfast most mornings. He is on a quest to tease out the roles that various blood components play in the formation of clots.

9 Oct 2013

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA.

8 Oct 2013

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

The oral hormone therapy conjugated equine estrogens, which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

1 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

FDA expands Hizentra administration options for people with primary immunodeficiency

CSL Behring announced today that the U.S. Food and Drug Administration has expanded the administration options for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, to include dosing once every two weeks (biweekly) for people diagnosed with primary immunodeficiency.

28 Sep 2013

Amendment to renal cancer TNM staging proposed

Patients with pT3a renal cell carcinoma have markedly worse survival rates if they have both fat invasion and renal vein thrombosis, rather than just one of these factors, a study shows.

24 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Choosing Wisely List released by The American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) today released a list of specific tests or procedures that are commonly ordered but not always necessary in orthopaedics as part of the Choosing Wisely- campaign, an initiative of the ABIM Foundation. The list identifies five targeted, evidence-based recommendations that can support conversations between patients and physicians about what care is really necessary.

12 Sep 2013

Study: Atorvastatin reduces inflammation, thrombogenesis in patients with acute ischemic stroke

The population of northeastern China has a high incidence of ischemic stroke. Previous studies have shown that intracranial large-artery atherosclerosis is one of the main causes of ischemic stroke, and that the mechanisms are related to inflammation and thrombosis of the affected arteries.

12 Sep 2013

Thrombosis News and Research

Latest Thrombosis News and Research

Ariad Ends Phase III Leukemia Drug Trial

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

Detecting dangerous blood clots in the form of simple urine test

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Simple urine test uses nanotechnology to detect dangerous blood clotting

Sexual dysfunction ‘ignored in COPD’

Six-month surgery delay ‘acceptable’ after DES implantation

Scientists introduce new approach to the production of synthetic heparin mimetics

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Understanding the biological players in clot formation could lead to new thrombotic therapies

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

GSK Sells Thrombosis Brands To Aspen For $1.13B

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

FDA expands Hizentra administration options for people with primary immunodeficiency

Amendment to renal cancer TNM staging proposed

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Choosing Wisely List released by The American Academy of Orthopaedic Surgeons

Study: Atorvastatin reduces inflammation, thrombogenesis in patients with acute ischemic stroke

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Thrombosis News and Research

Latest Thrombosis News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in